J Am Soc Nephrol
Background: DGF is acute kidney injury (AKI) defined as need for dialysis within one week of renal transplant. AKI is defined by a change in serum creatinine (SCr), however early recognition is limited by delay in creatinine rise. Accurate early biomarkers may lead to prevention or treatment of established AKI. The product of two novel biomarkers of cell cycle arrest, tissue Inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein (IGFBP-7) have shown promise in predicting AKI. In prior studies, TIMP-2*IGFPB-7 ≤0.3 had high negative predictive value, and ≥2 high positive predictive value for AKI. Aims - 1) Investigate the early diagnostic value of TIMP-2*IGFPB-7 for DGF; 2) Correlate TIMP-2*IGFPB-7 with long term graft function. Methods: This is a prospective, double-blinded single center observational study with goal enrollment of 150 transplant recipients. Urine TIMP-2*IGFBP-7 was measured in (ng/mL)2 /1000 with a commercial kit, Nephrocheck (Astute Medical, San Diego, CA) at 4-12 hours, 48-72 hours and 72-96 hours post-transplant. SCr was measured just prior to transplant, 1 week post-transplant, and at 1, 3, 6, 9 and 12 months post-transplant. Results: Thus far, 64 patient samples have been collected, 11 with DGF. Mean TIMP2*IGFPB-7 were 3.08 ± 0.63 vs 0.54 ± 0.23 (p-value
Leong R, Rodd C, Gomes KM, Savedchuk S, Kellerman PS. Diagnosis of early delayed graft function (DGF) using TIMP-2*IGFPB-7 product in transplant recipients: preliminary results. J Am Soc Nephrol. 2021;32(Suppl 2):670-671.